{"disease":{"id":"cerebrospinal-fluid","name":"cerebrospinal fluid"},"drugs":{"marketed":[{"drug_id":"prevnar-family","indication_name":"Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F in adults 19 through 64 years of age with cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevnar family","generic_name":"prevnar-family","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":"6494","mechanism":"Induces an immune response to Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F"},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cerebrospinal fluid shunts","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cerebrospinal fluid shunts","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cerebrospinal fluid shunts","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 18 years of age and older with cerebrospinal fluid leaks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 50 years of age and older with cerebrospinal fluid leaks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"prevenar-20","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, and 23F in adults 65 years of age and older with cerebrospinal fluid leaks","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prevenar 20","generic_name":"prevenar-20","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and HIV infection and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and sickle cell disease and cerebrospinal fluid leak","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with other conditions that increase the risk of invasive pneumococcal disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"15-valent-pneumococcal-conjugate-vaccine-pcv15","indication_name":"Prevention of invasive pneumococcal disease caused by 15 serotypes of Streptococcus pneumoniae in adults 18 years of age and older with cerebrospinal fluid leak.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"15-valent pneumococcal conjugate vaccine (PCV15)","generic_name":"15-valent-pneumococcal-conjugate-vaccine-pcv15","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"vaccine","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"mpnc-candidate","indication_name":"Prevention of invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae in adults 18 years of age and older with HIV infection and sickle cell disease and cerebrospinal fluid leak and cochlear implant and other conditions that increase the risk of invasive pneumococcal disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"mPnC candidate","generic_name":"mpnc-candidate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Specific protein or receptor involved in disease pathology","drug_class":"Novel therapeutic agent","quality_score":50,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":33,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06711731","title":"The Freiburg Registry on SpontanEous IntercrAnial Hypotension (SIH) & Post-duraL Puncture Headache (PDPH)","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University Hospital Freiburg","has_results":false},{"nct_id":"NCT04505423","title":"Evaluation of Outcomes Related to Cerebrospinal Fluid Drain Placement","phase":"","overall_status":"COMPLETED","enrollment_count":302,"lead_sponsor_name":"University of North Carolina, Chapel Hill","has_results":false},{"nct_id":"NCT05050864","title":"Stenting Versus Neurosurgical Treatment of Idiopathic Intracranial Hypertension.","phase":"NA","overall_status":"RECRUITING","enrollment_count":276,"lead_sponsor_name":"Fondation Ophtalmologique Adolphe de Rothschild","has_results":false},{"nct_id":"NCT02457546","title":"The EVICEL® Neurosurgery Phase III Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":234,"lead_sponsor_name":"Ethicon, Inc.","has_results":true},{"nct_id":"NCT04086550","title":"Evaluate the Safety and Efficacy of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":228,"lead_sponsor_name":"Polyganics BV","has_results":false},{"nct_id":"NCT07216157","title":"NoSeal Trial: Comparing Sealants Versus No Sealant for Preventing CSF Leak After Endonasal Skull Base Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Maria Sklodowska-Curie National Research Institute of Oncology","has_results":false},{"nct_id":"NCT02891070","title":"Efficacy and Safety of FS VH S/D 500 S-apr (Tisseel) as an Adjunct to Sutured Dural Repair in Cranial Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Baxter Healthcare Corporation","has_results":true},{"nct_id":"NCT06497634","title":"Effect of Spinal Needle Type on Optic Nerve Sheath Diameter","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":165,"lead_sponsor_name":"Bagcilar Training and Research Hospital","has_results":false},{"nct_id":"NCT04124523","title":"Perioperative CSF Leak Management - an Opinion Study","phase":"","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04057157","title":"Post-market Assessment of Biodesign Dural Repair Grafts","phase":"","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"Cook Research Incorporated","has_results":false},{"nct_id":"NCT04923867","title":"Suturable DuraGen™ PMCF Study","phase":"","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Integra LifeSciences Corporation","has_results":false},{"nct_id":"NCT01855425","title":"Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose","phase":"NA","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Carestream Health, Inc.","has_results":true},{"nct_id":"NCT04145544","title":"A Prospective, Randomized, Controlled Multi-center Study of ArtiFascia® Dural Repair Patch Compared With Commercially Available Dural Substitutes. To Evaluate the Safety and Effectiveness of ArtiFascia® in Subjects Requiring Dural Repair.","phase":"NA","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Nurami Medical Ltd","has_results":true},{"nct_id":"NCT05644535","title":"Cerebrospinal Fluid Gravity Correlation Analysis","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"First People's Hospital of Chenzhou","has_results":false},{"nct_id":"NCT04490629","title":"The Efficacy and Safety of a Latest Dural Substitute","phase":"NA","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07481396","title":"Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Chungnam National University Hospital","has_results":false},{"nct_id":"NCT07044037","title":"Analysis of Cerebrospinal Fluid in Patients With Cerebral Toxoplasmosis at CHSD (2004-2024)","phase":"","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"Centre Hospitalier de Saint-Denis","has_results":false},{"nct_id":"NCT03257735","title":"A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT03545984","title":"Evaluation of a Simulation Based Workshop in an Anesthesia Residency Program","phase":"NA","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"The Cleveland Clinic","has_results":true},{"nct_id":"NCT03830762","title":"Xanamem™ in Healthy Elderly Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Actinogen Medical","has_results":false},{"nct_id":"NCT03566602","title":"Evaluate the Safety and Performance of Dura Sealant Patch in Reducing CSF Leakage Following Elective Cranial Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Polyganics BV","has_results":false},{"nct_id":"NCT05898074","title":"Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Indiana University","has_results":false},{"nct_id":"NCT04471740","title":"Normal Pressure Hydrocephalus and Sleep Apnea","phase":"NA","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"University of Valencia","has_results":false},{"nct_id":"NCT06472505","title":"Using Polyglycolic Acid Mesh Prevents Cerebrospinal Fluid Leakage","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT04923399","title":"Transcriptome Sequencing Analysis of Whole Blood From Patients With Trigeminal Neuralgia","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT06743347","title":"Dynamic Measurement of Cerebrospinal Fluid in Healthy Subjects: Pilot Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Poitiers University Hospital","has_results":false},{"nct_id":"NCT04178629","title":"Ceftobiprole's Cerebrospinal Fluid Penetration in Patients With External Ventricular Derivation (CEFTO-EVD)","phase":"","overall_status":"UNKNOWN","enrollment_count":15,"lead_sponsor_name":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","has_results":false},{"nct_id":"NCT03276975","title":"A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT03104725","title":"Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":true},{"nct_id":"NCT06419855","title":"Study to Evaluate the Effectivity and Safety of BIOSCAFF®H Compared to DuraGen®, in Patients Undergoing Dural Repair","phase":"","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Top Health S.A.P.I DE C.V.","has_results":false},{"nct_id":"NCT03181464","title":"Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics","phase":"PHASE4","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT02902133","title":"Acetazolamide to Prevent Post Operative CSF Leak","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04351061","title":"Acetazolamide for the Prevention of Post Operative CSF Leak","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University of Miami","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}